MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, at 2:35 p.m. EDT. A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investor.igmbio.com/ne ...

Investors might want to bet on IGM Biosciences, Inc. (IGMS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual ...

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company's exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets. IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collab ...

Financial Performance - Cash and investments as of December 31, 2023, were $337.7 million, down from $427.2 million as of December 31, 2022[12]. - Collaboration revenue for the fourth quarter of 2023 was $0.7 million, compared to $0.4 million in the same quarter of 2022, and for the full year 2023, it was $2.1 million, up from $1.1 million in 2022[12]. - The net loss for the fourth quarter of 2023 was $60.7 million, or a loss of $1.01 per share, compared to a net loss of $52.6 million, or a loss of $1.19 per share, in Q4 2022[12]. - For the full year 2023, the net loss was $246.4 million, or a loss of $4.71 per share, compared to a net loss of $221.1 million, or a loss of $5.32 per share, in 2022[12]. Expenses - Research and Development (R&D) expenses for the fourth quarter of 2023 were $54.2 million, compared to $45.0 million in Q4 2022, and for the full year 2023, R&D expenses totaled $215.5 million, up from $179.3 million in 2022[12]. - General and Administrative (G&A) expenses for the fourth quarter of 2023 were $11.6 million, consistent with Q4 2022, while for the full year 2023, G&A expenses were $50.1 million, slightly up from $49.7 million in 2022[12]. - The company expects full year 2024 GAAP operating expenses to be between $210 million and $220 million, including approximately $40 million in non-cash stock-based compensation[9]. Cash Projections - The company anticipates ending 2024 with approximately $180 million in cash and investments, which is expected to fund operations into the second quarter of 2026[9]. Clinical Trials - Enrollment in the randomized clinical trial of aplitabart in metastatic colorectal cancer is ongoing, with a target of 110 patients[2]. - Two Phase 1b clinical trials of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis have been initiated, with expectations to generate meaningful initial clinical data by the end of 2024[2].

Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39045 IGM Biosciences, Inc. (Exact name of Registrant as specified in its Charter) De ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39045 IGM Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 77-0349194 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39045 IGM Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 77-0349194 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39045 IGM Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 77-0349194 (State or other jurisdic ...

IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Fred Schwarzer – Chief Executive Officer Misbah Tahir – Chief Financial Officer Chris Takimoto – Chief Medical Officer Mary Beth Harler – President-IGM Autoimmunity and Inflammation Bruce Keyt – Chief Scientific Officer Conference Call Participants Stephen Willey – Stifel Greg Harrison – Bank of America Michael Schmidt – Guggenheim Roger Song – Jefferies Joel Beatty – Baird Noah Eisenberg – J ...

Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39045 IGM Biosciences, Inc. (Exact name of Registrant as specified in its Charter) De ...